United States

Background
The bi-directional relationship between depression and prescription opioids is well-established. Evidence shows that adults with depression and non-cancer pain are more likely to remain on opioids and are at risk for opioid use disorder. In contrast, less is known about persistent opioid use and change in anxiety. Among chronic pain patients, opioid users are at higher risk for developing anxiety symptoms compared to those receiving other forms of pain management. However, it is unknown if continued use leads to worsening anxiety when compared to quitting. This study aims to determine if persistent opioid use is a risk factor for developing or worsening generalized anxiety disorder (GAD).

Methods
This prospective cohort study involved non-cancer pain patients (n=361) 18-70 years old starting a period of 30 to 90-day opioid use. Patients from Saint Louis University’s medical practice and the Henry Ford Health System self-administered web surveys or participated in telephone interviews. Difference in difference (D.I.D) analysis determined if change in opioid use was associated with change in GAD-7 scores. Outcome measures included mean GAD-7 score, change in GAD-7 score between baseline and 6 months, and threshold change from a GAD-7 score&lt;10 before and after adjusting for age, race, gender, depression, PTSD, anhedonia, substance use disorder, smoking, and alcohol use.

Results
At baseline, those who persistently used opioids had significantly higher GAD scores [6.4 (±5.9)] compared to those who quit [4.7 (±5.3)]. However, there was no significant difference in GAD score at 6 months between persistent users [5.3 (±5.5)] and quitters [5.2 (±5.8)]. The crude D-I-D analysis revealed no differences in GAD score change from baseline to 6 months between the groups (D.I.D = -1.58; 95% CI: -3.38, -0.23). An adjusted analysis revealed similarly insignificant results (D.I.D = -1.16; 95% CI: -2.94,0.62). Furthermore, among patients with negative GAD (score&lt;10) at baseline, there was no significant difference in risk of GAD (score&gt;=10) at 6 months, whether they persisted or not [crude RR = 1.10; 95% CI: 0.55,2.20); adjusted RR = 1.01 95% CI: 0.53,1.93)].

Conclusion
Patients who persisted vs. quit opioid use at 6 months did not differ in association with worsening or new-onset GAD. However, the results reveal a trend for persistent opioid users to have lower 6-month GAD scores. Additional analysis with a larger sample is needed to determine the characteristics of patients who persist yet experience a decrease in GAD symptoms compared to those who experience constant or worsening GAD.

AMA Research Challenge 2023

Persistent Opioid Use and the Development of Generalized Anxiety Disorder

Background
The bi-directional relationship between depression and prescription opioids is well-established. Evidence shows that adults with depression and non-cancer pain are more likely to remain on opioids and are at risk for opioid use disorder. In contrast, less is known about persistent opioid use and change in anxiety. Among chronic pain patients, opioid users are at higher risk for developing anxiety symptoms compared to those receiving other forms of pain management. However, it is unknown if continued use leads to worsening anxiety when compared to quitting. This study aims to determine if persistent opioid use is a risk factor for developing or worsening generalized anxiety disorder (GAD).

Methods
This prospective cohort study involved non-cancer pain patients (n=361) 18-70 years old starting a period of 30 to 90-day opioid use. Patients from Saint Louis University’s medical practice and the Henry Ford Health System self-administered web surveys or participated in telephone interviews. Difference in difference (D.I.D) analysis determined if change in opioid use was associated with change in GAD-7 scores. Outcome measures included mean GAD-7 score, change in GAD-7 score between baseline and 6 months, and threshold change from a GAD-7 score<10 before and after adjusting for age, race, gender, depression, PTSD, anhedonia, substance use disorder, smoking, and alcohol use.

Results
At baseline, those who persistently used opioids had significantly higher GAD scores [6.4 (±5.9)] compared to those who quit [4.7 (±5.3)]. However, there was no significant difference in GAD score at 6 months between persistent users [5.3 (±5.5)] and quitters [5.2 (±5.8)]. The crude D-I-D analysis revealed no differences in GAD score change from baseline to 6 months between the groups (D.I.D = -1.58; 95% CI: -3.38, -0.23). An adjusted analysis revealed similarly insignificant results (D.I.D = -1.16; 95% CI: -2.94,0.62). Furthermore, among patients with negative GAD (score<10) at baseline, there was no significant difference in risk of GAD (score>=10) at 6 months, whether they persisted or not [crude RR = 1.10; 95% CI: 0.55,2.20); adjusted RR = 1.01 95% CI: 0.53,1.93)].

Conclusion
Patients who persisted vs. quit opioid use at 6 months did not differ in association with worsening or new-onset GAD. However, the results reveal a trend for persistent opioid users to have lower 6-month GAD scores. Additional analysis with a larger sample is needed to determine the characteristics of patients who persist yet experience a decrease in GAD symptoms compared to those who experience constant or worsening GAD.

poster

Welcome to the **largest national, multi-specialty research** event featuring research from nearly 700 medical students, residents, fellows, and international medical graduates.

Use the buttons below or navigation menu to access the event.
 


[![](https://assets.underline.io/uploads/markdown_image/1/image/3e33a8c754cc49610b30950617d813e7.png)](https://underline.io/events/434/sessions?searchGroup=all)
 
[![](https://assets.underline.io/uploads/markdown_image/1/image/551404d429c4e274f9a54cbdd7081918.png)](https://underline.io/events/434/posters?searchGroup=all)
 
[![](https://assets.underline.io/uploads/markdown_image/1/image/677d92f566b880cebd36905fc738fc10.png)](https://underline.io/events/434/lounge)
 
[![](https://assets.underline.io/uploads/markdown_image/1/image/c7392833c7261c3874c5b43fa2f4df19.png)](https://underline.io/events/434/help-desk)
 

#### Event Details

The 2023 American Medical Association Research Challenge includes a poster symposium hall and a semifinals hall with the top scored research. **Log in at any time throughout the event to:**

* **View posters and presentations** on a variety of topics and specialties
* **Score posters in the semifinals** to help decide the top five finalists (AMA member exclusive opportunity)
* **Connect with participants** and provide feedback to help advance their research
* **Attend education sessions** with physician experts on key research topics

At the conclusion of this event, the AMA will announce the top five finalists who will advance to the AMA Research Challenge finals, present their research to an elite panel of judges, and compete to win a $10,000 grand prize sponsored by Laurel Road. 

### Grand Prize Sponsor

AMA would like to thank Laurel Road for sponsoring a $10,000 grand prize for the winner of the AMA Research Challenge. Laurel Road is not involved in the judging or scoring process to select the winner. The winner will be announced on February 4, 2024 during the AMA Research Challenge finals. Payment of the grand prize will be directly from Laurel Road. See the AMA Research Challenge Official Rules for terms and conditions.

![](https://assets.underline.io/uploads/markdown_image/1/image/611e331d4a0eba0920f240cfc04b4d77.png)

**There is no registration fee for this event! **

Register to explore research in a variety of topics. AMA members get exclusive access to score posters in the semifinals.

**Please use this link [here](https://www.ama-assn.org/about/events/ama-research-challenge) to register for free.**

Registration Is Required

Join the AMA Research Challenge poster symposium and semifinals to explore top research posters, score posters in the semifinals (an AMA member exclusive opportunity) and attend education sessions with experienced physicians to learn tips to advance your research and career. 

Background
Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory disorders of the GI tract that may cause symptoms leading to the alteration of dietary intake to control symptoms. There are recommended diets for treatment of inflammatory bowel disease (IBD), but many diets have low-quality evidence for efficacy. However, in an effort to relieve symptoms, patients or families may self-restrict certain foods, leading to the development of restrictive eating behaviors.
In 2013, avoidant-restrictive food intake disorder (ARFID) was added to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) to identify patients who actively restrict food intake leading to insufficient caloric/nutritional intake and causing at least one of the following complications: weight loss, nutritional deficiency, dependence on nutritional supplements, or psychosocial impairment. 
As ARFID is a relatively new diagnosis, the prevalence of this diagnosis in chronic disease states has not been well-characterized. A recent adult study measured the prevalence of ARFID in an adult IBD population, examined nutritional risk in the context of ARFID risk, and identified risk factors for ARFID in IBD patients. 28/161 (17%) patients had a positive ARFID risk score, as measured by the Nine-item ARFID Screening tool (NIAS).
Currently, there are no studies evaluating the prevalence of ARFID in pediatric patients with IBD. We estimate that the prevalence is high based on anecdotal food avoidances, particularly during a flare of symptoms. We also hypothesize that patients who have high ARFID risk scores may be more at risk for nutrition deficiencies. 
Methods
This is a prospective, observational cohort study of pediatric patients (age 0-17) with inflammatory bowel disease. Fifty patients will be enrolled. Participants complete surveys about eating behaviors and nutritional status after scheduled clinic visits. Study outcomes measured are ARFID risk score (calculated by the NIAS) and nutritional status (height and weight velocity z-scores, mid-upper arm circumference z-scores). 
Results
Based on recent guidelines, a positive ARFID risk score is defined as a score that meets at least one of the following criteria: ≥10 in the picky eating sub-score, ≥9 in the appetite sub-score, ≥10 in the fear sub-score, ≥24 in the total NIAS score Preliminary results suggest a prevalence of ARFID in participants based off a positive ARFID screen to be 21% (8/38 patients), compared to the estimated prevalence of ARFID in community pediatric populations of 2%.
Conclusion
We anticipate that the results of this study can help clinicians address nutritional deficiencies in pediatric IBD patients before it becomes detrimental to patients’ well-being. With the knowledge that pediatric IBD patients are more at risk of ARFID, their needs can be predicted by clinicians and dietitians to ensure proper care of patients.

Evaluating the Prevalence of Avoidant Restrictive Food Intake Disorder in Pediatric Patients with Inflammatory Bowel Disease

Background
Routine hepatic ultrasonography is the most used clinical imaging study in diagnosing chronic liver diseases (CLDs), including assessing hepatic steatosis, a common presentation of CLDs. However, data remain lacking on the performance of hepatic ultrasonography in assessing steatosis and factors that may impact the quality of its performance. This study evaluated the association of hepatic ultrasonography for the assessment of hepatic steatosis with histological hepatic steatosis and other related factors.
Methods
A single-center retrospective study of 188 patients with various CLDs, regular follow-ups, and liver biopsy at the UCIMC Liver Clinic.
Results
The mean age±SD was 57±13 years old. 93 patients were male (49.5%), and 44 (23.4%) had a BMI ≥ 30. Chronic hepatitis C (CHC, 20.8%) and B (17.5%), and non-alcoholic fatty liver disease (NAFLD, 29.0%) were the main CLDs. In this cohort, 89/187 (47.6%) patients had biopsy-proven hepatic steatosis (i.e., ≥ 5% of hepatocytes), 129/188 (68.6%) had ultrasonographic reports of hepatic steatosis, and 67/184 (36.4%) had ultrasonographic reports of hepatomegaly (i.e., ≥ 16.5 cm). The sensitivity and specificity of hepatic ultrasonography for assessing hepatic steatosis, compared to histological steatosis ≥ 5% (gold standard), was 85.4% (76/89 patients) and 46.9% (46/98 patients), respectively. Chi-square analysis showed that hepatic steatosis on ultrasonography was significantly associated with biopsy-proven hepatic steatosis (76/128, 59.4%, p<.01). Hepatic steatosis on ultrasonography was also significantly associated with age ≥ 65 years old (48/129, 37.2%, p=.02), histological evidence of ballooning degeneration (57/86, 66.3%, p<.01), Mallory-Denk bodies (20/60, 33.3%, p<.01), and portal/periportal fibrosis (66/98, 67.3%, p<.03). The frequency of hepatic steatosis diagnosed on ultrasonography was higher in those with NAFLD (45/92, 48.9%) than those with CHC (25/92, 27.2%) or CHB (22/92, 23.9%), but the difference was not significant (p=.08). Ultrasonographic-diagnosed hepatic steatosis was not significantly associated with BMI ≥ 30 (31/129, 24%, p=.76), elevated AST or ALT to ≥ 35 IU/L for males or ≥ 25 IU/L for females (90/111, 81.1%, p=.06 or 84/111, 75.7%, p=.77, respectively). In multivariate analysis, ultrasonographic-diagnosed hepatic steatosis was significantly associated with the presence of ballooning degeneration (95% CI: 1.25-20.72; p=.02) and portal/periportal fibrosis (95% CI: 1.29-11.14; p=.02) on liver biopsy, but not biopsy-proven hepatic steatosis (95% CI: 0.17-1.94; p=.37) or hepatomegaly on ultrasonography (95% CI: 0.71-7.33; p=.17).
Conclusion
Routine hepatic ultrasonography has good sensitivity, but low specificity in the assessment of hepatic steatosis. Histological hepatocytic ballooning degeneration and portal/periportal fibrosis were independently associated with hepatic steatosis detected by ultrasonography.

Association of Ultrasonographic Assessment of Hepatic Steatosis with the Presence Of Histological Steatosis and the Related Factors

There is very sparse data about prevalence
and outcome of gastric intestinal
metaplasia (GIM) in children. Our aim is to
review clinical and endoscopic findings in
children with GIM diagnosed by gastric
biopsy (bx) undergoing
esophagogastroduodenoscopy (EGD) for
various indications at our institution; also
review and compare above findings in
patients with repeat EGD in patients with
GIM.

Gastric Intestinal Metaplasia (GIM) in Children-How Common It Is And What Happens to It-A Pilot Project

Background:
Gastric cancer is among the top five cancer-burden in the United States and worldwide. The aim of our study is to investigate the racial variations in gastric carcinoma among individuals aged 50 years and above.

Methods:
We conducted a retrospective study using the SEER database, 17 registries, Nov 2021 Sub (2000- 2019) to identify individuals diagnosed with gastric cancer of 50 years and above age group. Age adjustment was done using the 2000 US population as a standard population. We collected racial/ethnic information related to incidence and incidence-based mortality of stomach cancer in our desired age groups.

Results:
This study included a total population of 109,352 patients of 50 years and above age with stomach cancer, out of which 71.6% were white, 12.9% were black, 14.2% were Asian or Pacific Islanders (API), and 0.9% were 1 American 1 Indian/ 1 Alaskan native (AI/AN). Based on incidence, all-cause mortality was 79.2% in white population, 78.9% in black, 71.5% in API and 82.8% in AI/AN. The incidence rate among white, black, API, and AI/AN were 20.6, 35, 36.3, and 21.3 per 100,000 population respectively, whereas the incidence-based mortality among the above races were 16.4, 28.9, 26.7, and 18.7 per 100,000 standard population. According to race, the incidence in white was 71.6% with incidence-based mortality of 79.2%. In Black incidence was 12.9% with incidence-based mortality of 78.9%. In American Indian incidence was 0.9% and incidence-based mortality was 82.8% and for Asian
incidence was 14.2% and incidence-based mortality of 71.5%.

Conclusion:
Our study outlines the racial disparities in the incidence and mortality of gastric carcinoma among individuals with gastric carcinoma among individuals aged 50 years and above. Although, gastric carcinoma is diagnosed mostly in the white population followed by Asian or Pacific islanders, black and then American Indians. The incidence rate and incidence-based mortality rates were highest among
Asian/Pacific Islanders and Black compared to that of white and American Indian/Alaskan natives. These findings help to address the disparities through interventions and healthcare policies targeted to improve gastric cancer incidence and outcomes across a diverse racial or ethnic population in the United
States. Further research is warranted to explore the underlying factors contributing to the racial disparities in gastric cancer.

Racial Disparities in Incidence and Mortality of Gastric Carcinoma of Individuals
Aged 50 Years and Above: A Population-Based Analysis

**Scoring is only possible in the semifinals hall**

**Abstract:**



A Retrospective Cohort Study: Utility of Fecal Occult Blood Test in the Acute Hospital Setting and Its Clinical Impacts

Association Between Mucosa-Associated Lymphoid Tissue (MALT) Surgery and Inflammatory Bowel Disease (IBD): A Systematic Review

Association Between Mucosa-Associated Lymphoid Tissue (MALT)
Surgery and Inflammatory Bowel Disease (IBD): A Systematic Review

Background: Although low-energy pelvic fractures seldom present with significant hemorrhage, early recognition of at-risk patients is essential. We aimed to identify predictors of blood use in this cohort.
Methods: A 5-year retrospective chart review was performed. Low energy mechanism was defined as falls of ≤ 5 feet. Fracture pattern was assigned using the AO/OTA system as A, B or C. Primary outcome was the need for ≥ 2 units of packed red blood cells (PRBC) in the first 48 hours. Bivariable analysis and logistic regression analysis were performed. A p-value ≤0.05 was considered significant.
Results: 350 patients were included with median age 88 (interquartile range [IQR] 85-92) and median Injury Severity Score (ISS) 5 (IQR 4-8). 346 (99%) had type A fractures. 17 (5%) required ≥2U PRBC/48 hours. In-hospital mortality rate was 4%. Factors associated with blood transfusion were systolic blood pressure (SBP) < 100 mmHg at any time in the emergency department (ED), trauma team activation, Abdomen-Abbreviated Injury Score and contrast extravasation on computed tomographic (CT) scan. By logistic regression, SBP< 100 mmHg (odds ratio [OR] 16.3, 95% confidence interval [CI] 5.33-40.2) and contrast extravasation (OR 4.29, 95% CI 1.11-15.3) were predictors. Both need for 2U PRBC (4/17 [24%] vs 9/332 [3%], p=0.002) and any SBP < 100 mmHg in the ED (6/41 [15%] vs 7/307 [2%], p=0.001) were associated with mortality.
Conclusion: Contrast extravasation on CT and hypotension in the ED predicted the need for transfusion of ≥ 2U of PRBC in patients with low energy pelvic fractures.

Hypotension in the Emergency Department and Contrast Dye Extravasation Predict Blood Transfusion in Low-Energy Pelvic Fractures

Background
Phenytoin has demonstrated improved wound healing, as well as analgesic and antibacterial properties. These effects occur through a variety of mechanisms, including increased collagen deposition, neovascularization, and fibroblast proliferation secondary to an up-regulation in platelet-derived growth factor expression. Systemic absorption of phenytoin is negligible when administered topically. Since the application of phenytoin in wound care is relatively uncommon, a systematic review may provide meaningful insights for clinicians and researchers alike.

Methods
Cochrane Library, Pubmed, Pubmed Central, and Medline were searched to find all relevant studies. Secondary hand searching was done using the references listed in other relevant papers. Irrelevant papers were removed while screening titles and abstracts. Selected randomized controlled trials (RCTs) and non-randomized controlled trials (NRCTs) were assessed for quality using a revised tool for assessing risk of bias in randomized trials (RoB 2), and the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) respectively. Data regarding the type of wounds studied, interventions, sample size, outcome measures, and reported adverse effects were collected and analyzed. 

Results
A total of 17 RCTs and 8 NRCTs were included. The wounds under study were predominantly of a single etiology; diabetic foot ulcers, decubitus ulcers, oral biopsy wounds, sutured episiotomies, leprotic ulcers, excisional wounds, fistulotomies, burns, abscess cavities, and traumatic wounds. A minority investigated wounds of multiple etiologies. Phenytoin was most often compared to inert controls such as normal saline, but there were trials with several other comparators including honey, silver sulfadiazine, Edinburgh University solution of lime, framycetin, and Aloe vera. The sample sizes of the included studies varied between 20 wounds to 200 wounds, with a median of 62 wounds. Phenytoin was found to hasten wound healing in the majority of trials. In addition, granulation tissue proliferation was improved, greater analgesic effects were produced, and there was an inhibition of bacterial contaminants as well as a reduction in wound discharge, slough, and exudates. Adverse effects were uncommon, minimal in severity, and transient in duration. The most common adverse effect observed was a burning sensation at the time of application.

Conclusion
Our review suggests that phenytoin may be a potentially beneficial adjunct to standard wound care. The topical administration of phenytoin can most likely be considered safe in most patients. We believe further study is warranted to investigate the optimal dose, frequency, and vehicle for application as well as the effects of phenytoin on other types of post-operative wounds.

Topical Phenytoin as an Adjunctive Treatment for Wounds

Background
Pancreatoduodenectomy (PD), an abdominal operation designed to remove pancreatic-head tumors, carries a substantial postoperative complication rate. Randomized data demonstrates that intraoperative fluid administration is associated with increased postoperative complications. However, it remains uncertain whether perioperative administration of crystalloids alone or in concert with colloids is more harmful. An initial literature search of [(Colloids versus crystalloids) OR (Crystalloids versus Colloids)] from 1987-2021 was performed on PubMed. Of the 116 eligible studies, 32(28%) concluded colloids are safer, 22(19%) concluded crystalloids are safer, and 62(53%) reached no consensus or determined equal efficacy. More importantly, only 16(13%) examined the effect of crystalloids vs colloids during hepatobiliary surgery, showing the lack of data. Therefore, we studied the relationship between volume and type of fluid administered during PD, specifically exploring intraoperative and 24 hours post-operative volume resuscitation.

Methods
We conducted a single-center retrospective analysis of patients undergoing PD from 2016-2021, for benign and malignant disease. Records were reviewed for patient demographic, disease, and treatment factors that include volume and type (crystalloid alone or combined with colloid) of fluid administered both intraoperatively and 24 hours post-operatively. The Clavien-Dindo complication score was calculated to determine if fluid ratios significantly affected patient outcome. Linear regression was performed to analyze the relationship between crystalloid administration and Clavien-Dindo score and ratio of crystalloid to colloid and Clavien-Dindo score.

Results
During the interval studies, there were 491 patients who underwent PD. 248(50%) were female, 366(74%) had a malignant preoperative diagnosis, and 176(36%) had preoperative chemotherapy. Median age was 65(range: 20-67) and average BMI was 25(range: 14.8-56). 212(43%) patients received solely perioperative crystalloid. There was no significant correlation between the amount of crystalloid administered and the Clavien-Dindo score (y=-0.0007841±0.002527,R^2:0.0006774,p:0.7568,F:0.09625). 276(56%) patients were administered ratios of perioperative crystalloid to colloid. There was a high positive significant correlation between ratio of crystalloid and colloid administered and the Clavien-Dindo score (y=0.7755±0.3955,R^2:0.01383,p:0.0509,F:3.844).

Conclusion
Based on a sample of 491 patients, increasing ratios of crystalloid to colloid appears to be significantly correlated with higher rates of complication in PD, as quantified by higher Clavien-Dindo scores. It is meaningful that patients who received any amount of colloid had worse outcomes. In future operative procedures, it may be necessary to balance crystalloid and colloid infusion or avoid colloid infusion to improve postoperative outcomes. Future work includes performing a multivariate analysis to see how other modifiable risk factors prior to PD can affect post-operative outcomes.

The Association of Total Volume and Ratio of Perioperative Crystalloid to Colloid Fluid Administration on Complications Following Pancreatoduodenectomy

Next from AMA Research Challenge 2023

Evaluating the Prevalence of Avoidant Restrictive Food Intake Disorder in Pediatric Patients with Inflammatory Bowel Disease